Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675557 | 1.00 | TSHR (0.46) | TSHRTP53TDP1PPARDLPAR3 | |
| SCHEMBL28232878 | 0.88 | TSHR (0.40) | TSHRTP53TDP1PPARD | |
| SCHEMBL10348398 | 0.88 | TSHR (0.40) | TSHRTP53TDP1PPARD | |
| SCHEMBL16675550 | 0.87 | TSHR (0.36) | TSHRTP53TDP1 | |
| SCHEMBL923145 | 0.82 | — | — | |
| SCHEMBL15293628 | 0.81 | HCAR2 (0.39) | TSHRTP53TDP1PPARDNR1I2 | |
| SCHEMBL9751249 | 0.80 | — | — | |
| SCHEMBL15163745 | 0.78 | MAPT (0.46) | TSHR | |
| SCHEMBL12845876 | 0.78 | TSHR (0.38) | TSHRTP53TDP1ACHE | |
| SCHEMBL1679837 | 0.76 | TSHR (0.57) | TSHRTP53TDP1PPARDLPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9950067-B2 | Trans carotenoids, their synthesis, formulation and uses | Diffusion Pharmaceuticals, LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170202798-A1 | BIPOLAR TRANS CARTENOID SALTS AND THEIR USES | DIFFUSION PHARMACEUTICALS LLC (US) | 2017-07-20 | — | — | US | disclosed |
| US-9604899-B2 | Bipolar trans carotenoid salts and their uses | DIFFUSION PHARMACEUTICALS LLC (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160199490-A1 | TRANS CAROTENOIDS, THEIR SYNTHESIS, FORMULATION AND USES | Diffusion Pharmaceuticals, LLC | 2016-07-14 | — | — | US | disclosed |
| US-20140051759-A1 | BIPOLAR TRANS CAROTENOID SALTS AND THEIR USES | DIFFUSION PHARMACEUTICALS LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20120095099-A1 | Trans carotenoids, their synthesis, formulation and uses | DIFFUSION PHARMACEUTICALS LLC (US) | 2012-04-19 | — | — | US | disclosed |
| US-8017653-B2 | Bipolar trans carotenoid salts and their uses | DIFFUSION PHARMACEUTICALS LLC (US) | 2011-09-13 | — | — | US | disclosed |
| US-20110196038-A1 | Bipolar trans carotenoid salts and their uses | DIFFUSION PHARMACEUTICALS LLC (US) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160199490-A1 | TRANS CAROTENOIDS, THEIR SYNTHESIS, FORMULATION AND USES | TTPA, RBP4, TXNRD2 | TSHR 2140/4885TP53 3984/4885TDP1 4025/4885 |
| US-20140051759-A1 | BIPOLAR TRANS CAROTENOID SALTS AND THEIR USES | RBP4, MB, SLC6A12 | TSHR 1232/4885TP53 4467/4885TDP1 2317/4885 |
| US-20170202798-A1 | BIPOLAR TRANS CARTENOID SALTS AND THEIR USES | TXNRD2, CYP11B2, CYP11B1 | TSHR 1403/4885TP53 4101/4885TDP1 3458/4885 |
| US-20110196038-A1 | Bipolar trans carotenoid salts and their uses | RBP4, MB, SLC6A12 | TSHR 1232/4885TP53 4467/4885TDP1 2317/4885 |
| US-20120095099-A1 | Trans carotenoids, their synthesis, formulation and uses | TTPA, RBP4, TXNRD2 | TSHR 2140/4885TP53 3984/4885TDP1 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.